FDA approves NEW obesity drug Zepbound that has been dubbed the ‘King Kong’ of weight-loss shots and helps people lose up to 50lbs

Eli Lilly’s new weight-loss drug, Zepbound, has been approved by the US Food and Drugs Administration (FDA).

The active ingredient in the drug, tirzepatide, has already been approved to treat Type 2 diabetes in Eli Lilly’s Mounjaro, which has been used off-label for obesity.

Zepbound is the latest drug to join the blockbuster weight-loss drug lineup that includes Novo Nordisk’s Ozempic and Wegovy.

The FDA approved Zepbound for obese adults or overweight adults with at least one weight-related condition.

In clinical trials, the drug has been shown to help people lose up to 52 pounds in 16 months.

In a phase three trial, the new shot saw participants lose an average of 22.5 percent of their weight, making it the most effective weight loss medication on the market.

Zepbound is administered by injection once a week, and the dosage must be increased over four to 20 weeks to achieve the target dosages of 5 milligrams (mg), 10 mg or 15 mg once weekly.

The maximum dosage of Zepbound is 15 mg once weekly.

More to follow…